BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Koichi Watashi, Guoxin Liang, Masashi Iwamoto, Hiroyuki Marusawa, Nanako Uchida, Takuji Daito, Kouichi Kitamura, Masamichi Muramatsu, Hirofumi Ohashi, Tomoko Kiyohara, Ryosuke Suzuki, Jisu Li, Shuping Tong, Yasuhito Tanaka, Kazumoto Murata, Hideki Aizaki, Takaji Wakita. Interleukin-1 and Tumor Necrosis Factor-α Trigger Restriction of Hepatitis B Virus Infection via a Cytidine Deaminase Activation-induced Cytidine Deaminase (AID)Journal of Biological Chemistry 2013; 288(44): 31715 doi: 10.1074/jbc.M113.501122
2
G. Gentile, R. Foà. Viral infections associated with the clinical use of monoclonal antibodiesClinical Microbiology and Infection 2011; 17(12): 1769 doi: 10.1111/j.1469-0691.2011.03680.x
3
Gholam Hossein Alishiri, Gholam Ali Ghorbani, Salimzadeh Ahmad. Prevalence of Hepatitis B Infection in Rheumatoid Arthritis PatientsPakistan Journal of Biological Sciences 2013; 16(15): 747 doi: 10.3923/pjbs.2013.747.750
4
Jie Ruan, Shuo Sun, Xin Cheng, Pengyu Han, Yinge Zhang, Dianxing Sun. Mitomycin, 5-fluorouracil, leflunomide, and mycophenolic acid directly promote hepatitis B virus replication and expression in vitroVirology Journal 2020; 17(1) doi: 10.1186/s12985-020-01339-5
5
Wu Zhi-Feng, Zhou Le-Yuan, Zhou Xiao-Hui, Gao Ya-Bo, Zhang Jian-Ying, Hu Yong, Zeng Zhao-Chong. TLR4-Dependent Immune Response Promotes Radiation-Induced Liver Disease by Changing the Liver Tissue Interstitial Microenvironment during Liver Cancer RadiotherapyRadiation Research 2014; 182(6): 674 doi: 10.1667/RR13630.1
6
Anil Seetharam, Robert Perrillo, Robert Gish. Immunosuppression in Patients with Chronic Hepatitis BCurrent Hepatology Reports 2014; 13(3): 235 doi: 10.1007/s11901-014-0238-2
7
Chien-Yuan Chen, Feng-Ming Tien, Aristine Cheng, Shang-Yi Huang, Wen-Chien Chou, Ming Yao, Jih-Luh Tang, Hwei-Fang Tien, Wang-Huei Sheng. Hepatitis B reactivation among 1962 patients with hematological malignancy in TaiwanBMC Gastroenterology 2018; 18(1) doi: 10.1186/s12876-017-0735-1
8
John A. Thompson, Bryan J. Schneider, Julie Brahmer, Stephanie Andrews, Philippe Armand, Shailender Bhatia, Lihua E. Budde, Luciano Costa, Marianne Davies, David Dunnington, Marc S. Ernstoff, Matthew Frigault, Brianna Hoffner, Christopher J. Hoimes, Mario Lacouture, Frederick Locke, Matthew Lunning, Nisha A. Mohindra, Jarushka Naidoo, Anthony J. Olszanski, Olalekan Oluwole, Sandip P. Patel, Sunil Reddy, Mabel Ryder, Bianca Santomasso, Scott Shofer, Jeffrey A. Sosman, Momen Wahidi, Yinghong Wang, Alyse Johnson-Chilla, Jillian L. Scavone. Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network 2019; 17(3): 255 doi: 10.6004/jnccn.2019.0013
9
Mohammad Reza Hedayati-Moghaddam, Hossein Soltanian, Masoud Behzadifar. Occult Hepatitis B Virus Infection Prevalence Among Different Populations of Iran: A Systematic Review and Meta-AnalysisHepatitis Monthly 2020; 20(6) doi: 10.5812/hepatmon.101722
10
Mehdi Zobeiri. Occult Hepatitis B: Clinical Viewpoint and ManagementHepatitis Research and Treatment 2013; 2013: 1 doi: 10.1155/2013/259148
11
Rosa Maria Morillas, David López Sisamón. Reactivación de la hepatitis B asociada a agentes inmunodepresores y a quimioterapia. Historia natural, factores de riesgo y recomendaciones para prevenirlaMedicina Clínica 2019; 152(3): 107 doi: 10.1016/j.medcli.2018.08.018
12
Paul Martin, Daryl T.-Y. Lau, Mindie H. Nguyen, Harry L.A. Janssen, Douglas T. Dieterich, Marion G. Peters, Ira M. Jacobson. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 UpdateClinical Gastroenterology and Hepatology 2015; 13(12): 2071 doi: 10.1016/j.cgh.2015.07.007
13
Rosa Maria Morillas, David López Sisamón. Reactivation of hepatitis B associated with immunosuppressants and chemotherapy. Natural history, risk factors and recommendations for preventionMedicina Clínica (English Edition) 2019; 152(3): 107 doi: 10.1016/j.medcle.2018.12.006
14
Amanda Abramson, Alan Menter, Robert Perrillo. Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: A review and recommendations for managementJournal of the American Academy of Dermatology 2012; 67(6): 1349 doi: 10.1016/j.jaad.2012.04.036
15
J. Samal, M. Kandpal, P. Vivekanandan. Molecular Mechanisms Underlying Occult Hepatitis B Virus InfectionClinical Microbiology Reviews 2012; 25(1): 142 doi: 10.1128/CMR.00018-11
16
April W. Armstrong, Lakshi Aldredge, Paul S. Yamauchi. Managing Patients With Psoriasis in the Busy ClinicJournal of Cutaneous Medicine and Surgery 2016; 20(3): 196 doi: 10.1177/1203475415623508
17
LEI XU, ZENG TU, GE XU, YUWEI WANG, WANLONG PAN, XINGXING ZHAN, QIANG LUO, YUAN HUANG, JUAN CHEN, AILONG HUANG. Epirubicin directly promotes hepatitis B virus (HBV) replication in stable HBV-expressing cell lines: A novel mechanism of HBV reactivation following anticancer chemotherapyMolecular Medicine Reports 2014; 9(4): 1345 doi: 10.3892/mmr.2014.1973
18
Yoichi Iwafuchi, Yuko Oyama, Takashi Morita, Akira Kamimura, Shigeru Miyazaki, Ichiei Narita. De novo acute hepatitis B in myeloperoxidase-specific anti-neutrophil cytoplasmic autoantibody-related microscopic polyangiitis treated with corticosteroidsCEN Case Reports 2013; 2(1): 28 doi: 10.1007/s13730-012-0033-2
19
Alissa Visram, Jordan J. Feld. Defining and grading HBV reactivationClinical Liver Disease 2015; 5(2): 35 doi: 10.1002/cld.426
20
M.L. Manzano Alonso, I. Fernández Vázquez. Reactivación de la hepatitis B: prevención y tratamientoMedicine - Programa de Formación Médica Continuada Acreditado 2012; 11(9): 568 doi: 10.1016/S0304-5412(12)70349-9
21
Chien-Yuan Chen, Sheng-Yi Huang, Aristine Cheng, Wen-Chien Chou, Ming Yao, Jih-Luh Tang, Woei Tsay, Wang-Huei Sheng, Hwei-Fang Tien, Chien-Wei Su. High Risk of Hepatitis B Reactivation among Patients with Acute Myeloid LeukemiaPLOS ONE 2015; 10(5): e0126037 doi: 10.1371/journal.pone.0126037
22
Hyo Jin Kim, Dong Hyun Sinn, Nam Jun Kim, Jung Hee Kim, Eun Kim, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Byung Chul Yoo. Stopping Preemptive Antiviral Therapy for Hepatitis B Virus Can Be Considered for Patients with Favorable PredictorsDigestive Diseases and Sciences 2015; 60(12): 3794 doi: 10.1007/s10620-015-3812-8
23
W.-J. Mayet. Differenzialdiagnose der Transaminasenerhöhung bei rheumatischen ErkrankungenZeitschrift für Rheumatologie 2015; 74(2): 137 doi: 10.1007/s00393-014-1501-1
24
Jing Fang, Wenge Li, Min Tan, Xiangxin Peng, Zhao Tan, Wenbo Wang. Effect of different hepatitis B infection status on the prognosis of active lupus nephritis treated with immunosuppression: a retrospective analysis of 177 patientsInternational Journal of Rheumatic Diseases 2018; 21(5): 1060 doi: 10.1111/1756-185X.13313
25
Antonio Guardiola Arévalo, Rafael Gómez Rodríguez, Marta Romero Gutiérrez, Ana Zaida Gómez Moreno, Almudena García Vela, Raquel Sánchez Simón, Cesar Gómez Hernando, Eva María Andrés Esteban. Características y evolución de la infección crónica por virus de la hepatitis B antígeno e negativoGastroenterología y Hepatología 2017; 40(2): 59 doi: 10.1016/j.gastrohep.2016.11.002
26
Sema Sezgin Göksu, Şerife Bilal, Hasan Şenol Coşkun. Hepatitis B reactivation related to everolimusWorld Journal of Hepatology 2013; 5(1): 43-45 doi: 10.4254/wjh.v5.i1.43
27
Antonio Guardiola Arévalo, Rafael Gómez Rodríguez, Marta Romero Gutiérrez, Ana Zaida Gómez Moreno, Almudena García Vela, Raquel Sánchez Simón, Cesar Gómez Hernando, Eva María Andrés Esteban. Characteristics and course of chronic hepatitis B e antigen-negative infectionGastroenterología y Hepatología (English Edition) 2017; 40(2): 59 doi: 10.1016/j.gastre.2016.11.009
28
Zhi-Feng Wu, Xiao-Hui Zhou, Yun-Wen Hu, Le-Yuan Zhou, Ya-Bo Gao, Xiu-Hua Peng, Xiao-Hua Yang, Jian-Ying Zhang, Yong Hu, Zhao-Chong Zeng. TLR4-dependant immune response, but not hepatitis B virus reactivation, is important in radiation-induced liver disease of liver cancer radiotherapyCancer Immunology, Immunotherapy 2014; 63(3): 235 doi: 10.1007/s00262-013-1504-9
29
Meng-Tzu Weng, Chien-Chih Tung, Yuan-Ting Chang, Yew-Loong Leong, Yu-Ting Wang, Jau-Min Wong, Shu-Chen Wei. Trends of Medication Usage and Associated Outcomes for Taiwanese Patients with Inflammatory Bowel Disease from 2001 to 2015Journal of Clinical Medicine 2018; 7(11): 394 doi: 10.3390/jcm7110394
30
Giuseppe Murdaca, Francesca Spanò, Miriam Contatore, Andrea Guastalla, Elena Penza, Ottavia Magnani, Francesco Puppo. Infection risk associated with anti-TNF-α agents: a reviewExpert Opinion on Drug Safety 2015; 14(4): 571 doi: 10.1517/14740338.2015.1009036
31
Jeong Won Jang. Management of Patients with Hepatitis B Virus Infection Who Receive Immunosuppressive Treatment or ChemotherapyKorean Journal of Medicine 2012; 82(2): 149 doi: 10.3904/kjm.2012.82.2.149
32
K. Awasthi, Asmita Das, T. Prasad. Molecular Markers in MycologyFungal Biology 2017; : 335 doi: 10.1007/978-3-319-34106-4_16
33
J. Koskinas, M. Tampaki, P.P. Doumba, E. Rallis. Hepatitis B virus reactivation during therapy with ustekinumab for psoriasis in a hepatitis B surface-antigen-negative anti-HBs-positive patientBritish Journal of Dermatology 2013; 168(3): 679 doi: 10.1111/bjd.12120
34
Robert Hirten, Keith Sultan, Ashby Thomas, David E Bernstein. Hepatic manifestations of non-steroidal inflammatory bowel disease therapyWorld Journal of Hepatology 2015; 7(27): 2716-2728 doi: 10.4254/wjh.v7.i27.2716
35
Ahmet Murt, Tugrul Elverdi, Ahmet Emre Eskazan, Ayse Salihoglu, Muhlis Cem Ar, Seniz Ongoren, Zafer Baslar, Teoman Soysal. Hepatitis B reactivation in hematopoietic stem cell transplanted patients: 20 years of experience of a single center from a middle endemic countryAnnals of Hematology 2020;  doi: 10.1007/s00277-020-04206-z
36
M. Mouler Rechtman, E. O. Burdelova, I. Bar-Yishay, M. Ben-Yehoyada, S. Fishman, Z. Halpern, A. Shlomai. The metabolic regulator PGC-1α links anti-cancer cytotoxic chemotherapy to reactivation of hepatitis B virusJournal of Viral Hepatitis 2013; 20(1): 34 doi: 10.1111/j.1365-2893.2012.01622.x
37
Nuria Dominguez, Maria Luisa Manzano, Raquel Muñoz, Ana Martin, Inmaculada Fernandez, Gregorio Castellano. Late reactivation of occult hepatitis B virus infection in a patient with chronic lymphocytic leukemia after rituximab and fludarabine-based regimenLeukemia & Lymphoma 2015; 56(4): 1160 doi: 10.3109/10428194.2014.947978
38
Shinta Mizuno, Yoshiyuki Yamagishi, Hirotoshi Ebinuma, Nobuhiro Nakamoto, Mai Katahira, Aya Sasaki, Michiie Sakamoto, Hidekazu Suzuki, Takanori Kanai, Toshifumi Hibi. Progressive liver failure induced by everolimus for renal cell carcinoma in a 58-year-old male hepatitis B virus carrierClinical Journal of Gastroenterology 2013; 6(2): 188 doi: 10.1007/s12328-013-0371-4
39
Eleonora Teplinsky, Derrick Cheung, Ilan Weisberg, Ramon E. A. Jacobs, Martin Wolff, James Park, Kent Friedman, Franco Muggia, Komal Jhaveri. Fatal hepatitis B reactivation due to everolimus in metastatic breast cancer: case report and review of literatureBreast Cancer Research and Treatment 2013; 141(2): 167 doi: 10.1007/s10549-013-2681-0
40
Yutaka Tsutsumi, Reiki Ogasawara, Naohiro Miyashita, Junji Tanaka, Masahiro Asaka, Masahiro Imamura. HBV reactivation in malignant lymphoma patients treated with rituximab and bendamustineInternational Journal of Hematology 2012; 95(5): 588 doi: 10.1007/s12185-012-1050-9
41
Fernando Bessone, Melisa Dirchwolf. Management of hepatitis B reactivation in immunosuppressed patients: An update on current recommendationsWorld Journal of Hepatology 2016; 8(8): 385-394 doi: 10.4254/wjh.v8.i8.385
42
Klaas Poelstra, Jai Prakash, Leonie Beljaars. Drug targeting to the diseased liverJournal of Controlled Release 2012; 161(2): 188 doi: 10.1016/j.jconrel.2012.02.011
43
Lei Xu, Zeng Tu, Ge Xu, Jie-Li Hu, Xue-Fei Cai, Xing-Xing Zhan, Yu-Wei Wang, Yuan Huang, Juan Chen, Ai-Long Huang. S-phase arrest after vincristine treatment may promote hepatitis B virus replicationWorld Journal of Gastroenterology 2015; 21(5): 1498-1509 doi: 10.3748/wjg.v21.i5.1498
44
A. El Mekkaoui, Z. Benbrahim, O. El Mesbahi, A. Ibrahimi, N. Aqodad. Traitement préemptif de la réactivation de l’hépatite virale B des patients sous chimiothérapie anticancéreuseJournal Africain du Cancer / African Journal of Cancer 2014; 6(1): 47 doi: 10.1007/s12558-013-0299-4
45
Giuseppe Murdaca, Simone Negrini, Marco Pellecchio, Monica Greco, Chiara Schiavi, Francesca Giusti, Francesco Puppo. Update upon the infection risk in patients receiving TNF alpha inhibitorsExpert Opinion on Drug Safety 2019; 18(3): 219 doi: 10.1080/14740338.2019.1577817
46
Jing Fang, Wenge Li, Xiangxin Peng, Zhao Tan, Min Tan, Cong Zhang, Wenbo Wang, Zhihong Xu, Gumin Zhou. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving immunosuppressive therapy for glomerulonephritis: a retrospective analysisInternational Urology and Nephrology 2017; 49(3): 475 doi: 10.1007/s11255-016-1487-5
47
Dan Yang, Longchao Liu, Danming Zhu, Hua Peng, Lishan Su, Yang-Xin Fu, Liguo Zhang. A mouse model for HBV immunotolerance and immunotherapyCellular & Molecular Immunology 2014; 11(1): 71 doi: 10.1038/cmi.2013.43
48
Maarten A. A. van de Klundert, Formijn J. van Hemert, Hans L. Zaaijer, Neeltje A. Kootstra, Sang-Hoon Ahn. The Hepatitis B Virus X Protein Inhibits Thymine DNA Glycosylase Initiated Base Excision RepairPLoS ONE 2012; 7(11): e48940 doi: 10.1371/journal.pone.0048940
49
David J. Weber, William A. Rutala. Plotkin's Vaccines2018; : 1402 doi: 10.1016/B978-0-323-35761-6.00072-9
50
Apostolos Koffas, Grace E Dolman, Patrick TF Kennedy. Hepatitis B virus reactivation in patients treated with immunosuppressive drugs: a practical guide for cliniciansClinical Medicine 2018; 18(3): 212 doi: 10.7861/clinmedicine.18-3-212